We've Updated Our Privacy Policy



We’ve Updated Our Privacy Policy The good news is, nothing material has changed. FeedBlitz is continuing to adhere to the same high standards we set ourselves from the start, in terms of both how we run our business and our obligations to you, our users.   The better news is, the updated privacy policy is I think not only clearer, it’s actually helpful, in that it contains things like links to third party sites where you can control how third party services we use (such as Google Analytics) treat your information. Light reading it is not, but it’s not exactly “War and Peace” either. If you care about how information about you is collected and used, it’s worth a read. In more or less plain English, this is what our updated privacy policy says: You have the right to control your personal information. FeedBlitz never sells, rents or buys email addresses. List owners can see the information you give them as part of our services. FeedBlitz uses cookies, tracking and logging to make FeedBlitz work and tell list owners about activity on their lists. FeedBlitz emails globally, but is a US-based business with a US-based infrastructure. So why update it? Well, periodically, we review what we do and how we do it. As part of that process, our lawyers urged us to update our privacy policy to be both clearer, and to reflect modern realities. For example, the part about our servers being in the US turns out to be fairly important for non-US users. We didn’t have that before. Anyway, lawyers are expensive (but for good reason), and it seems silly to waste all that money! You can find our freshly updated privacy policy here.           Related Stories Managing Images in Your Newsletter Template Just Got Easier I Need This Post to Go Out ASAP – How Do I Do That? On Being a Company, as well as a Business   • Email to a friend • View comments • Track comments • More Blitz Bits Are you a FeedBlitz Affiliate? Monetizing Your Mailings by Selling Digital Content A Word on Monetizing your Mailings How to Start Monetizing Your Mailings Is Gmail About to Wreck your Email Marketing?   The latest videos from FeedBlitz Support How to deliver an incentive to some subscribers, not all Autoresponder How to Send a Newsflash Without Audience Segmentation The latest videos from FeedBlitz Support How to deliver an incentive to some subscribers, not all Autoresponder How to Send a Newsflash Without Audience Segmentation     Click here to safely unsubscribe from "FeedBlitz News." Click here to view mailing archives, here to change your preferences, or here to subscribe • Privacy Email subscriptions powered by FeedBlitz, LLC, 365 Boston Post Rd, Suite 123, Sudbury, MA 01776, USA.

   

   

ScienceDaily: Top News

---

• Novel targeted drug shows promise against advanced small cell lung cancer
• Nivolumab immunotherapy helps patients with advanced bladder cancer
• New drug 'retrains' immune system to fight aggressive bladder cancer

Novel targeted drug shows promise against advanced small cell lung cancer Posted: 05 Jun 2016 09:41 AM PDT The experimental "smart-bomb" drug rovalpituzumab tesirine (Rova-T) appears safe and shows efficacy in treating patients with advanced small cell lung cancer, according to results from a first-in-human clinical trial.

Nivolumab immunotherapy helps patients with advanced bladder cancer Posted: 05 Jun 2016 09:41 AM PDT The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results.

New drug 'retrains' immune system to fight aggressive bladder cancer Posted: 05 Jun 2016 09:39 AM PDT A new drug that harnesses the immune system to attack tumors is highly effective against advanced bladder cancer, according to the results of an international clinical trial.

You are subscribed to email updates from Latest Science News -- ScienceDaily. To stop receiving these emails, you may unsubscribe now.	Email delivery powered by Google
Google Inc., 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States

ScienceDaily: Health & Medicine News

---

• Novel targeted drug shows promise against advanced small cell lung cancer
• Nivolumab immunotherapy helps patients with advanced bladder cancer
• New drug 'retrains' immune system to fight aggressive bladder cancer

Novel targeted drug shows promise against advanced small cell lung cancer Posted: 05 Jun 2016 09:41 AM PDT The experimental "smart-bomb" drug rovalpituzumab tesirine (Rova-T) appears safe and shows efficacy in treating patients with advanced small cell lung cancer, according to results from a first-in-human clinical trial.

Nivolumab immunotherapy helps patients with advanced bladder cancer Posted: 05 Jun 2016 09:41 AM PDT The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results.

New drug 'retrains' immune system to fight aggressive bladder cancer Posted: 05 Jun 2016 09:39 AM PDT A new drug that harnesses the immune system to attack tumors is highly effective against advanced bladder cancer, according to the results of an international clinical trial.

You are subscribed to email updates from Health & Medicine News -- ScienceDaily. To stop receiving these emails, you may unsubscribe now.	Email delivery powered by Google
Google Inc., 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States